A Mutation-Based Reverse Vaccinology Approach Considering Variability in Epitopes to Combat Multi-Strains: A Study...

Area of Science:

• Virology
• Immunology
• Vaccine Development
• Bioinformatics

Background:

• Lassa virus (LASV) poses a significant public health threat due to its strain variability, limiting current therapeutic effectiveness.
• Developing a vaccine that addresses LASV's genetic diversity is crucial for effective disease control.

Purpose of the Study:

• To design and evaluate a mutation-based, epitope-derived vaccine against Lassa virus (LASV) by incorporating variable regions of the glycoprotein.
• To assess the immunogenicity, structural integrity, and binding affinity of the proposed vaccine candidates.

Main Methods:

• Reverse vaccinology approach to identify B-cell (LBL) and T-cell (MHC-I, MHC-II) epitopes from LASV glycoprotein.
• In silico construction of wild and mutated epitope-based vaccines with an adjuvant (PADRE) and 6xHis-Tag.
• Computational analysis including 3D structure prediction, molecular docking with TLR-2, molecular dynamics simulation, immune simulation, and in silico cloning in E. coli.

Main Results:

• Identified 2 LBL, 21 MHC-I, and 8 MHC-II epitopes, with wild and mutated variants constructed.
• Vaccine constructs exhibited favorable 3D structure quality (91.5% wild, 91% mutated) and high population coverage (94%).
• Strong binding affinity to TLR-2 (-11.1 kcal/mol wild, -19.9 kcal/mol mutated), stable molecular dynamics, robust immune response, and efficient expression in E. coli.

Conclusions:

• The integrated in silico approach successfully designed mutation-based epitope vaccines against LASV.
• The developed vaccine candidates demonstrate potential for broad protection against diverse LASV strains.
• This strategy offers a promising platform for developing next-generation vaccines against variable viruses.